[Beta-2-microglobulin in clinical practice].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000175:diagnosis; D003424:Crohn Disease / Q000175:diagnosis; D003928:Diabetic Nephropathies / Q000175:diagnosis; D005260:Female; D005921:Glomerulonephritis / Q000175:diagnosis; D006084:Graft Rejection; D006801:Humans; D007231:Infant, Newborn; D007674:Kidney Diseases / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000175:diagnosis; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis; D008297:Male; D007690:Polycystic Kidney Diseases / Q000175:diagnosis; D011507:Proteinuria / Q000175:diagnosis; D012859:Sjogren's Syndrome / Q000175:diagnosis; D001613:beta 2-Microglobulin / Q000032:analysis*
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001613:beta 2-Microglobulin
Beta-2-mikroglobulin v klinicheskoĭ praktike.